Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Stifel Financial Corp

Stifel Financial Corp cut its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 15.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 182,505 shares of the company's stock after selling 33,635 shares during the quarter. Stifel Financial Corp owned approximately 0.12% of Ionis Pharmaceuticals worth $7,311,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Ionis Pharmaceuticals by 3.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company's stock valued at $363,000 after acquiring an additional 261 shares during the period. Nicollet Investment Management Inc. increased its position in shares of Ionis Pharmaceuticals by 1.5% in the 3rd quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company's stock valued at $817,000 after acquiring an additional 294 shares during the period. Amalgamated Bank grew its position in Ionis Pharmaceuticals by 3.1% during the 3rd quarter. Amalgamated Bank now owns 9,957 shares of the company's stock worth $399,000 after purchasing an additional 300 shares during the period. GAMMA Investing LLC increased its holdings in Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company's stock valued at $27,000 after buying an additional 303 shares in the last quarter. Finally, Itau Unibanco Holding S.A. grew its position in shares of Ionis Pharmaceuticals by 40.9% in the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company's stock valued at $43,000 after purchasing an additional 314 shares during the period. Institutional investors own 93.86% of the company's stock.

Ionis Pharmaceuticals Stock Down 1.1 %

Shares of IONS traded down $0.40 during midday trading on Friday, reaching $36.61. The stock had a trading volume of 1,070,411 shares, compared to its average volume of 1,333,200. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The company's fifty day simple moving average is $37.52 and its two-hundred day simple moving average is $42.28. The company has a market cap of $5.78 billion, a price-to-earnings ratio of -15.00 and a beta of 0.35. Ionis Pharmaceuticals, Inc. has a 1-year low of $33.33 and a 1-year high of $54.44.

Insiders Place Their Bets

In other news, EVP Eric Swayze sold 1,194 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48. Following the completion of the sale, the executive vice president now owns 33,713 shares in the company, valued at approximately $1,278,396.96. This represents a 3.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Brett P. Monia sold 6,630 shares of the firm's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the transaction, the chief executive officer now directly owns 167,393 shares in the company, valued at approximately $6,369,303.65. This represents a 3.81 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,877 shares of company stock valued at $299,578 in the last ninety days. Insiders own 2.71% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on IONS shares. Royal Bank of Canada reissued an "outperform" rating and set a $70.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. Needham & Company LLC reiterated a "buy" rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Thursday, November 7th. Piper Sandler cut their target price on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Guggenheim reduced their price objective on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a "buy" rating on the stock in a report on Wednesday, October 9th. Finally, Wells Fargo & Company lowered their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating for the company in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $60.65.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.